CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
According to the company, this new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to biodefense and pandemic settings for anti-infectious vaccines.
CEL-1000 has previously been shown to increase the antigenicity of hepatitis B virus (HBV). In challenge studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents. CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.